Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vildagliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 17/20 | 1.00 |
| ▸ | FAP | Q12884 | 1/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 1.00 |
| ▸ | PREP | P48147 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vildagliptin SCHEMBL29369942 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL27193113 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL10031674 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16153676 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL665401 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16155482 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16579 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16823370 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL665400 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL671629 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 354 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011101861-A1 | PROCESS FOR PREPARATION OF DPP-IV INHIBITORS | MSN LABORATORIES LIMITED (IN) | 2011-08-25 | — | — | WO | claimed |
| US-20100144811-A1 | COMBINATION | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-06-10 | — | — | US | claimed |
| EP-1893236-A2 | DIRECT COMPRESSION FORMULATION OF DPP-IV INHIBITORS AND GLITAZONES, AND PROCESS | Novartis AG (CH) | 2008-03-05 | — | — | EP | claimed |
| US-20070032420-A1 | Treating diabetes with glucagon-like peptide-1 secretagogues | ENTELOS, INC. | 2007-02-08 | — | — | US | claimed |
| US-20070027197-A1 | Pharmaceutical composition and method for the treatment of diseases using HMG-CoA reductase inhibitors and insulin secretion enhancers or sensitizers | DAMON ROBERT E | 2007-02-01 | — | — | US | claimed |
| WO-2006135693-A2 | DIRECT COMPRESSION FORMULATION OF DPP-IV INHIBITORS AND GLITAZONES, AND PROCESS | NOVARTIS AG (CH) | 2006-12-21 | — | — | WO | claimed |
| EP-1715893-A2 | DIRECT COMPRESSION FORMULATION AND PROCESS | Novartis Pharma AG. (CH) | 2006-11-02 | — | — | EP | claimed |
| WO-2006084757-A2 | COMBINATION OF CA/MG SALT OF VALSARTAN WITH AN ANTIDIABETIC AGENT | NOVARTIS AG (CH) | 2006-08-17 | — | — | WO | claimed |
| EP-1686994-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | claimed |
| WO-2005117861-A1 | USE OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-12-15 | — | — | WO | claimed |
| WO-2005067976-A2 | DIRECT COMPRESSION FORMULATION AND PROCESS | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | claimed |
| WO-2005049022-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | claimed |
| EP-3266457-B1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SHIRE HUMAN GENETIC THERAPIES (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260076972-A1 | ANTIDIABETIC MEDICATIONS | BOEHRINGER INGELHEIM INT (DE) | 2026-03-19 | — | — | US | disclosed |
| US-20250312456-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2025-10-09 | — | — | US | disclosed |
| EP-4620522-A2 | A COMBINATION COMPRISING VILDAGLIPTIN AND METFORMIN | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2025-09-24 | — | — | EP | disclosed |
| WO-2005049022-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049088-A2 | COMBINATION OF A DPP IV INHIBITOR AND AN ANTIOBESITY OR APPETITE REGULATING AGENT | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| EP-1419173-A2 | PEPTIDES THAT BIND TO ATHEROSCLEROTIC LESIONS | Novartis AG (CH) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003014145-A2 | PEPTIDES THAT BIND TO ATHEROSCLEROTIC LESIONS | NOVARTIS AG (CH) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144811-A1 | COMBINATION | GPR119, INSR, AGTR1 | DPP4 112/4885FAP 2055/4885DPP8 167/4885 |
| US-20070027197-A1 | Pharmaceutical composition and method for the treatment of diseases using HMG-CoA reductase inhibitors and insulin secretion enhancers or sensitizers | HMGCR, PCSK9, INSR | DPP4 632/4885FAP 2196/4885DPP8 808/4885 |
| US-20250312456-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 82/4885DPP8 5/4885 |
| US-20260076972-A1 | ANTIDIABETIC MEDICATIONS | IAPP, DPP4, PYGL | DPP4 2/4885FAP 863/4885DPP8 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.